When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.
Immunotherapy Combo Reduces Solid Tumors in Mice
Immunotherapy Combo Reduces Solid Tumors in Mice
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.
When tumor cells are infected with an oncolytic virus carrying a modified CD19 gene, they become targets for CAR T cells engineered to recognize this molecular marker.
The US Food and Drug Administration’s approval of an engineered herpesvirus for the treatment of melanoma marks the first oncolytic virus to enter the market.